Abstract
ObjectivesTo assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have